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Abstract: Patients (pts) with head and neck squamous cell carcinoma (HNSCC) have different
epidemiologic, clinical, and outcome behaviors in relation to human papillomavirus (HPV) infection
status, with HPV-positive patients having a 70% reduction in their risk of death. Little is known
about the molecular heterogeneity in HPV-related cases. In the present study, we aim to disclose
the molecular subtypes with potential biological and clinical relevance. Through a literature review,
11 studies were retrieved with a total of 346 gene-expression data points from HPV-positive HNSCC pts.
Meta-analysis and self-organizing map (SOM) approaches were used to disclose relevant meta-gene
portraits. Unsupervised consensus clustering provided evidence of three biological subtypes
in HPV-positive HNSCC: Cl1, immune-related; Cl2, epithelial–mesenchymal transition-related;
Cl3, proliferation-related. This stratification has a prognostic relevance, with Cl1 having the best
outcome, Cl2 the worst, and Cl3 an intermediate survival rate. Compared to recent literature, which
identified immune and keratinocyte subtypes in HPV-related HNSCC, we confirmed the former
and we separated the latter into two clusters with different biological and prognostic characteristics.
At present, this paper reports the largest meta-analysis of HPV-positive HNSCC studies and offers a
promising molecular subtype classification. Upon further validation, this stratification could improve
patient selection and pave the way for the development of a precision medicine therapeutic approach.
Keywords: self-organizing map; head and neck cancer; treatment de-escalation; HP; molecular
subtypes; tumor microenvironment
1. Introduction
Worldwide, head and neck squamous cell carcinoma (HNSCC) affects more than 550,000 patient
cases/year with around 380,000 deaths annually [1]. Traditionally, alcohol exposure and tobacco
smoking are identified as exogenous risk factors. However, human papillomavirus (HPV) infection,
caused predominantly by HPV type 16, is currently recognized as an independent causal factor for the
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development of HNSCC. Since the 1990s, there was a significant increase in HPV-related HNSCC in
western countries, whilst the incidence of HPV-negative HNSCC is globally declining [2,3], in parallel
with the decline in tobacco smoking rates. This high incidence of HPV-positive cases establishes
HNSCC as one of the most common HPV-related cancers, second only to cervical cancer [4]. Moreover,
it is estimated that the annual incidence could increase and eventually surpass the annual incidence of
cervical cancer by 2020. Previous epidemiological studies showed that around 25% of all HNSCCs are
related to HPV infection, with a tendency for the oropharynx (OPSCC) to be the specific site, compared
to infection in other sites (oral cavity, larynx, and hypopharynx) [5]. It is known that HPV-related
HNSCC patients have different epidemiologic and clinical behaviors in comparison with HPV-negative
HNSCC patients, allowing the identification of HPV-positive HNSCC as a specific distinct disease
with peculiar prognostic characteristics [6]. In fact, HPV-positive HNSCC is diagnosed at a younger
age than HPV-negative HNSCC, and the five-year survival rate for HPV-positive HNSCC is 60–90%
as compared with 20–70% for HPV-negative HNSCC [7], conferring a more favorable prognosis for
HPV-positive HNSCC patients. The differences in outcomes between HPV-positive and HPV-negative
tumors were already provided, and a multitude of molecular differences comparing HPV-negative
and HPV-positive HNSCC patients were reported [8–10]. However, a clear biological picture behind
their broad diversity is not yet elucidated. Moreover, considering the better prognosis of HPV-positive
HNSCC patients compared with their HPV-negative HNSCC counterparts and the median younger
age of patients at diagnosis, the question about how to treat HPV-positive patients requires an answer.
De-escalation of treatment protocols, for this subgroup of patients, is currently ongoing [11], with the
final aim being to reduce the intensity of treatments (both chemoradiation and surgery) and the
burden of treatment-related toxicities over the next few years. A further investigation on HPV-related
HNSCC is needed. As already reported in the literature, in addition to the diversity of HPV-positive
HNSCC compared with HPV-negative HNSCC, it is possible to also observe an intrinsic biological
heterogeneity in the HPV-positive HNSCC. In particular, we refer to Keck et al. [12], who identified
two different clusters on the basis of their gene expression, and to Zhang et al. [13], who classified
these two groups as HPV-positive immune-related (HPV-IMU) and HPV-positive with keratinocyte
differentiation (HPV-KRT) HNSCC. Both of these studies had the ability to explore the biology related
to HPV infection, unfortunately without showing a significant survival difference.
High-throughput technologies allow the assessment of thousands of features, posing challenges to
data analysis. To deal with increased data complexity, researchers apply machine learning approaches to
improve biological knowledge via intuitive visualization, even at single-sample resolution. This allows
questions, such as biomarker discovery and functional biological information mining, to be addressed.
A particular method, self-organizing maps (SOM), provides important benefits including dimension
reduction, multidimensional scaling, visualization capabilities over alternative methods such as
non-negative matrix factorization, and hierarchical clustering [14]. SOM gained immediate attention
in the bioinformatics field, and early microarray studies reported its application [15,16]. Since then,
a number of studies on different cancer types proved its robustness [17,18].
In the present analysis, we focused our attention on HPV-positive HNSCC with annotated gene
expression data and clinical annotations by exploiting a meta-analysis approach. We applied the SOM
machine learning method on a total of 346 HPV-positive tumor samples. This allowed us to dissect the
molecular heterogeneity of the disease and to make suggestions for de-escalation treatment.
2. Results
2.1. Case Material
In order to dissect the molecular heterogeneity in HPV-positive HNSCC, 11 eligible published
studies reporting gene expression data were selected for a systematic survey (Table S1, Supplementary
Materials). Of these studies, all but one utilized microarray technology for gene expression analysis,
and, in the majority of cases, HPV status was assessed with qPCR or HPV genotyping. The resulting
Cancers 2019, 11, 1057 3 of 24
meta-analysis dataset, containing 346 samples and 8254 EntrezID genes, was used for the genomic
analysis. HPV infection was assessed by p16 immunohistochemistry (IHC) (13 cases, 4%) or DNA
or RNA from HPV testing (333, 96%) (Table S1, Supplementary Materials). All the methods used are
recognized and utilized in clinical practice [19].
According to the clinical information (Table 1), a male preponderance (83%) and median age of
58.7 years (range, 35–87) were observed, in line with the epidemiological data reported in the literature.
The main subsite of origin was the oropharynx (68%), followed by the oral cavity (17%), larynx (6%),
and hypopharynx (3%). Stages, assessed following malignant tumor classification system (TNM
edition 7, American Joint Committee on Cancer, AJCC), were divided into stages I–II (35), stages III–IV
(229), and information not available (82). Locally advanced stages (III–IV) were the most represented
(66%), followed by not available (24%) and early stages (I–II; 10%). Survival data were available for
197 cases (57%) and not present for 149 cases (43%). Smoking habits were reported for 245 patients
(169 smokers, 76 never smokers), and were unknown for 101 patients (Table 1).
Table 1. Demographic and clinical data of the head and neck squamous cell carcinoma (HNSCC)
human papillomavirus (HPV)-positive patients entered in the meta-analysis.
Characteristics No. %
Age, years
(median; range) 57 (35–87) 77%
Not available 78 23%
Gender (male:female ratio) 287/59 83%/17%
Subsite
Oropharynx 235 68%
Oral cavity 59 17%
Larynx 20 6%
Hypopharynx 10 3%
Not available 22 6%
Stage according to TNM edition 7
Stage I–II 35 10%
Stage III–IV 229 66%
Not available 82 24%
Smoking
Smoker 169 49%
Not smoker 76 22%
Not available 101 29%
Availability of follow-up data
Yes 197 57%
No 149 43%
Total 346 100%
2.2. HPV-Positive HNSCC Tumor Clusters: First-Level Self-Organizing Map (SOM) and Unsupervised
Clustering Analysis
We applied the SOM machine learning algorithm to convert the meta-analysis dataset into a matrix
of meta-gene expression data. Starting from the 8254 genes, we imposed the log-intensity variation
p-value < 0.01, and a data matrix of 3498 genes was yielded. These 3498 genes were aggregated
in meta-genes (average 10 genes each), resulting in a matrix of 18 × 18 meta-genes. Consensus
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unsupervised clustering was applied on the meta-gene data, revealing three clusters of samples.
The cluster had well-defined boundaries, as shown by the consensus heatmap (Figure 1a). To exclude
the existence of under-represented clusters, the consistency of sample assignment was evaluated by
silhouette plot analysis. The resulting clustering configuration was appropriate (Figure 1b), since most
samples in each cluster had a positive value (average < s >: Cluster 1, Cl1 = 0.68; Cluster 2, Cl2 =
0.53; Cluster 3, Cl3 = 0.48). Only seven samples (two belonging to Cl2 and five belonging to Cl3),
corresponding to 2% of the entire case material, had negative values but were in the range between
−0.01 and −0.04. These seven samples were assigned by silhouette analysis, as follows: two Cl2
samples to Cl1, three Cl3 samples to Cl2, and three Cl3 samples to Cl1. We assessed the sample
size adequacy by estimating the power for the detection of the three clusters; the robustness of the
classification was ensured since at least 87% of genes had a power level of 0.9 (Figure S1, Supplementary
Materials). By training the SOM algorithm, each sample was portrayed by displaying its molecular
fingerprint. The generated subtype SOM images revealed a series of adjacent mosaic tiles coherently
over- or under-expressed, and the resulting gallery of SOM portraits was used to intuitively visualize
the coherent cluster patterns. In this way, we highlighted cluster-specific tiles in the SOM portraits,
independent of the patient’s individuality (Figure 1c).
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Figure 1. Human papillomavirus (HPV)-positive head and neck squamous cell carcinoma
(HNSCC) tumor clusters: first-level self-organizing map (SOM) and unsupervised clustering analysis.
(a) Consensus matrix heatmap imposing three clusters: Cl1 (n = 134; 39%), Cl2 (n = 104; 30%), and
Cl3 (n = 108; 31%). The consensus values are reported in a range from 0 (white, samples that never
cluster together) to 1 (blue, samples showing the highest clustering affinity). (b) Silhouette plot
analysis. The samples are ranked based on silhouette values (S) in each cluster. The heights indicate a
strong similarity of th samples within th ir clusters compared with the samples bel nging to other
clusters. The colors in the lower bar show th predicted embership by silhouette analy is; the l r
t t l t i i t f ll l it t ti f t
.
cluster-specific tiles hig lighted. The expr ssion patterns are translated into a color code indicating
over- and under-expression in a range from red to blue spo s, respectively.
l i vestigated the influence related to technical sources of v riability n our findings.
An alluvial diagram was used t show t e three-cluster m mbership, based on the study of origin
and the platform used for the expression profiling (Figure 2). The percentage of variation, explained
by these v riables, was investigated compared with the variation a sociated with the r s t l t
stratification, and this is summarized in the violin plots (Figure S2, Supplementary Materials).
Our findings supported the biological value behind our three-subtype stratification, with a negligible
influence of technical covariates.
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Figure 2. Alluvial diagram. In the diagram, each of the blocks corresponds to the number of features,
and the stream fields between the blocks represent changes in the composition of the different blocks.
The sizes of the blocks are proportional to the number of samples. We explored the cluster membership
taking into account (i) the study of origin of each sample (11 strata); (ii) the different technology
platforms used for expression profiling (five strata). Study of the origin: χ2 test = 12.08, p-value = 0.913;
Platform χ2 test = 5.93, p-value = 0.655.
2.3. - ositive l ster i ilarity elatio ships: eco d- evel
e sec -le el a al sis i esti ate t e si ilarit relati s i s a t e first-le el
sa le rtraits.
e a lie t ree ifferent sa ple si ilarity a roaches to esti ate t e t al ista ces a
s les, se et e e e ressi t si ifferent etrics and algorith s. e first
r c , i e e e t c e t l sis (I ), is l e t ree cl sters s rti t e i e tifie
str tific ti , lt t e ries et ee t e ere t strictl efi e ( i re , left el).
iti l i f r ti c l r tri fr t t r i t c ts (c t ,
c ent 2, and component 3): the projections onto the compone t 1/compone t two axes (Figure 3a,
right lower panel) segr ated Cluster 1 (Cl1, green spots) from Cl2 and Cl3 (blue a r s ts,
r s cti l ); r, r i s f i sit l l s isti ct i r it t cl r
s r ti . t c tr r , t c t /c t t r s r c si r , l
l r re cle rl i i e (Figure 3a, right upper panel).
s sec alter ti tri , e investi t a correlatio net or approach: t res lti
str ct re was visualized into a graph to ighlight the correlati n network (Figure 3b), and it confirmed
the pres nce of a main cluster including Cl1 with few connections to Cl2 and Cl3.
t ir r e l it cli ist - s r t r t r s l ti f
i or-joining (NJ) clustering, which projects the relationships among samples in phylogenetic tr es
(Figure 3c). The NJ dendrogram w s able to disclose finer details th n the previous approaches, nd it
revealed inherent substructures and their conn ctions in each cluster. By visual inspection, most Cl1
samples were segregat d into clearly different branch s from Cl2 and Cl3 branches, which, in contrast,
appeared tightly correlated.
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specific molecular features for each subtype. Indeed, the resulting map defined three over-expression
regions, each of them located in distinct corners of the map. These regions corresponded to SOM
clusters of co-regulated meta-genes (Figure 4a). The association of meta-genes to each cluster in precise
map locations (left panels) and to a bar plot of expression intensity (right panels) better confirmed and
defined the differences between subtypes: 54, 93, and 57 meta-genes had positive correlations with
Clusters 1, 2, and 3, respectively (r = 0.77, r = 0.53, r = 0.67) (Figure 4b).
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Figure 4. Subtype characterization by group overexpression maps. (a) The 18 × 18 map of meta-genes
summarizes the expression landscapes over the three subtypes; according to this analysis, co-regulated
meta-genes are located in the opposite corners of the map. (b) Detailed analysis of metagenes
overexpressed in each subtype: map location (left panels) and bar plot of expression intensity (right
panels). The bar plot represents the average meta-gene expression of each sample for the selected tiles.
Cancers 2019, 11, 1057 9 of 24
2.4. Tumor Microenvironment Landscape
The xCell tool was applied for the detection and evaluation, if present, of any differences in the three
clusters, regarding microenvironment components. According to a dimensionality reduction technique
(t-distributed stochastic neighbor embedding, t-SNE), we obtained two-dimensional coordinates that
clearly segregated the three molecular clusters. It provided evidence about the existence of unique and
defined biological subtypes (Figure 5a). To better disclose the properties of each subtype, the composite
scores of immune cells (ImmuneScore), stromal cells (StromaScore), and the score of keratinocytes were
calculated. Cl1, compared to Cl2 and Cl3, was characterized by enrichment of immune components
(p-value = 9.9 × 10−29) (Figure 5b) and under-expression of keratinocytes (p-value = 2.03 × 10−32)
(Figure 5c). On the contrary, Cl2 and Cl3 showed similar enrichment in keratinocytes, but a lower
immunoscore. Cl2 and Cl3 were clearly separated when compared in terms of stromal components,
with Cl3 significantly decreased (p-value = 6.3 × 10−18) compared with the two other two subtypes
(Figure 5d).
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Figure 5. Tumor microenvironment landscape. (a) Visualization of the immune and “other cell”
infiltrates assessed by xCell. Individual patients are summarized based on two-dimensional coordinates
from the t-distributed stochastic neighbor embedding (t-SNE) method. The notched boxplots show the
ImmuneScores (p-value = 9.9 × 10−29) (b), keratinocytes scores (p-value = 2.03 × 10−32) (c), and stromal
cell infiltrates (p-value = 6.3 × 10−18) (d) split into the three different subtypes.
2.5. Functional Analyses of Subtypes
To disclose the biological properties associated with each of the three resulting clusters, further
functional characterization was performed using Gene Set Enrichment Analysis (GSEA). GSEA is
a method used to test the overrepresentation of genes in gene sets, which are characterized by
independent studies. We investigated the “Hallmark” gene set collection representing specific
well-defined biological processes. In particular, our analysis provided evidence of a specific enrichment
for each cluster. Cl1 showed enrichment in immune-related hallmarks, such as “allograft rejection”,
“IFN, interferon gamma”, and “IL6 JAK STAT3 signaling”; Cl2 overexpressed genes related to the
hallmarks “epithelial–mesenchymal transition” (EMT), “myogenesis”, and “hypoxia”; Cl3 displayed
enrichment in proliferation-related hallmarks, e.g., “E2F targets” and “G2M checkpoint” (Table 2 and
Figure 6).
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Table 2. Gene-sets significantly up-regulated in each cluster.
Gene-set ID HALLMARKGene-Set Name Genes
a NES b
Nom
p-Value
FDR
q-val
Cl1 vs. Cl2 and Cl3
GS-1 ALLOGRAFT REJECTION(immune resp) 130 2.89 <0.00001 <0.00001
GS-2 INTERFERON GAMMARESPONSE 151 2.18 <0.00001 <0.00001
GS-3 IL6 JAK STAT3SIGNALING 60 1.94 <0.00001 <0.00001
GS-4 INFLAMMATORYRESPONSE 132 1.76 <0.00001 0.0018
GS-5 KRAS SIGNALING UP 114 1.75 <0.00001 0.0019
Cl2 vs. Cl1 and Cl3
GS-1
EPITHELIAL
MESENCHYMAL
TRANSITION
140 3.01 <0.00001 <0.00001
GS-2 MYOGENESIS 119 2.42 <0.00001 <0.00001
GS-3 COAGULATION 77 2.23 <0.00001 <0.00001
GS-4 ANGIOGENESIS 19 2.02 <0.00001 <0.00001
GS-5 HYPOXIA 133 1.90 <0.00001 <0.00001
GS-6 HEDGEHOG SIGNALING 17 1.89 0.0020 <0.00001
GS-7 UV RESPONSE DN 97 1.78 <0.00001 0.0020
GS-8 APICAL JUNCTION 137 1.78 <0.00001 0.0020
Cl3 vs. Cl1 and Cl2
GS-1 E2F TARGETS 143 2.56 <0.00001 <0.00001
GS-2 G2M CHECKPOINT 150 2.24 <0.00001 0.0020
GS: geneset; thresholds: FDR ≤ 0.005; NES≥1.75, a Number of total genes present in the geneset, b NES = normalized
enrichment score.
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Figure 6. Visualization of the Gene Set Enrichment Analysis (GSEA) functional analysis for each of
the three clusters. The boxplots show how the gene set Z score (GSZ) values (depicted in y-axis)
are distributed within each of the three clusters (Cl1, green; Cl2, blue; Cl3 red). In each row,
comparisons of the GSZ score values for the two most enriched hallmark gene sets are shown:
for Cl1, over-expression is shown for the “immune response” hallmark (p-value 1.09 × 10−40) and
“interferon (IFN)-gamma response” hallmark (p-value = 9.32 × 10−14); for Cl2, enrichment is shown in
the “epithelial–mesenchymal transition (EMT)” hallmark (p-value = 4.30 × 10−33) and “myogenesis”
hallmark (p-value = 9.68 × 10−19); for Cl3, over-expression is shown in the “E2F targets” hallmark
(p-value = 2.68 × 10−18) and “G2M checkpoint” (p-value 2.10 × 10−13). The p-values were obtained by
means of Kruskal–Wallis tests.
2.6. HPV Presence/Integration and Its Association with Clusters
We investigated the association between HPV viral integration and our three clusters, using the
data provided by Koneva et al. [20]. Table S2 (Supplementary Materials) shows the contingency table
for the TCGA cases analyzed in Koneva et al., reaching a significant association of χ2 =12.32 and a
p-value = 0.00212; the relative presence of HPV integrated cases in each subtype increased in the order
Cl1 < Cl3 < Cl2, with relative frequencies of 0.45, 0.77, and 1, respectively. Moreover, we explored the
expression of viral genes (E2, E4, and E5). The expression patterns in Cluster 2 are consistent with viral
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integration. When integrated, the expression of the E2 gene is reduced, since it is truncated along with
downstream genes such as E4 and E5 (Figure S3).
2.7. Prognostic Values of the Three-Subtype Classification
Due to the robust analysis revealing three distinct HPV-positive HNSCC subtypes, we aimed to
investigate their associations with overall survival as the clinical endpoint. Outcome data (i.e., overall
survival; OS) were available for 75/134 Cl1 patients, 56/108 Cl2 patients, and 66/104 Cl3 patients, for a
total of 197 patients. As depicted in Figure 7a, the results showed a significantly better outcome for Cl1
subtype patients, with a survival probability at 60 months of 0.809, and a worst outcome for Cl3 and
Cl2 subtypes, with a survival probability at 60 months of 0.47 and 0.197, respectively (log-rank p-value
= 4.76 × 10−9).Cancers 2019, 11, x 12 of 22 
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proportional to radioresistance (high index = radioresistance), while the 172-gene model is directly 
proportional to the risk of recurrence. Stratification by both signatures reached p-value = 8.76 × 10−13 
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were predicted as belonging to Cl1, Cl2, and Cl3, respectively. The cases, entered into the three 
identified subtypes, were used for the Kaplan–Meier analysis, yielding a p-value = 0.0152 (log-rank 
test). 
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Among HNSCCs, the HPV-positive tumors are an independent entity with specific clinical and 
molecular characteristics. Moreover, inside the HPV-positive subgroup, it is additionally possible to 
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such as large tumor burden and smoking history, correlate with a worse prognosis, but the biological 
mechanisms elucidating the complexity of the HPV-positive subgroup are still not fully understood. 
In the present meta-analysis of transcriptomic data, we applied a rigorous and up-to-date 
bioinformatics analysis to 346 HPV-positive HNSCCs with published sample data. To the best of our 
knowledge, this is the largest cohort of HPV-positive HNSCCs analyzed up until now. Specifically, 
our study identified three tumor subtypes, and it further dissected a population, which was 
previously divided into only two subgroups by published studies [12,13,24]. In agreement with these 
findings, we clearly identified an immune-associated cluster (named Cl1 in our analysis). In addition, 
we stratified the remaining patients (previously described as one “keratinocyte subtype” cluster 
[13,24]) into two well distinct subtypes with clearly defined biological and prognostic characteristics. 
The stratification refinement could be attributed not only to the dimension of the analyzed cohort 
(from two to three times larger than in previous studies), but also to the application of the NJ analysis, 
which revealed a degree of heterogeneity moving from Cl2 to Cl3 samples with disjointed branches. 
In general, HPV-related HNSCCs are known to have better outcomes when compared with 
HPV-negative HNSCCs [25]. The observed overall survival of our cohort of patients is aligned with 
the reported prognostic data. However, our analysis displayed a specific prognosis for each cluster, 
identifying those HPV-positive cases with the best, intermediate, and poorest prognoses. 
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interpreting their different outcomes. 
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those patients identified as having low-risk HPV-related HNSCC [25]. Additionally, Cl1 was clearly 
i re 7. Prognostic evaluation of the three-subtype stratification. (a) Survival analysis on the
meta-analysis dataset (MetaHPVpos). The 197 cases, e tered into the three subtypes (75/134 Cl1
patients; 56/108 Cl2 patients; 66/104 Cl3 patients), were used for the Kaplan–Meier analysis, yielding
a log-rank score of p-value = 4.76 × 10−9. The endpoint was overall survival. (b) Gene-signature.
Two models were evaluated: (i) radiosensitivity index (RSI), (ii) the 172-gene prognostic model. RSI is
directly proportional to radioresistance (high index = radioresistance), while the 172-gene model is
directly proportional to the risk of recurrence. Stratification by both signatures reached p-value = 8.76
× 10−13 and p-value = 7.98 × 10−22 for the RSI and 172-gene model, respectively. (c) Validation on
GSE112026. The 47 cases belonging to GSE112026 were stratified based on our three subtypes: 18, 18,
and 11 cases were predicted as belonging to Cl1, Cl2, and Cl3, respectively. The cases, entered into
the three identified subtypes, were used for the Kaplan–Meier analysis, yielding a p-value = 0.0152
(log-rank test).
Furthermore, we applied two different gene expression published signatures to the 197
HPV-positive HNSCC patients with available follow-up information: (i) the 172-gene model,
a prognostic model for HNSCC [21]; (ii) the radiosensitivity index (RSI) [22], a gene signature
developed as a pan-marker of cellular radiosensitivity. In order to assess whether and to what extent
the signatures were associated with HPV-related subtypes, we applied the algorithms developed [21,22]
to our cohort. The resulting scores were compared to the three-subtype stratification. A significant
relationship was found between our stratification and these molecular signatures (Figure 7b). In detail,
the Cl1 subtype showed the lowest 172-gene signature related score, meaning that Cl1 has the minimum
predicted risk, as confirmed by OS. Furthermore, Cl1 displayed the lowest RSI value, which predicted
its radiosensitivity. On the contrary, Cl2 subtype exhibited the highest score in the 172-gene signature,
and the maximum RSI score, compared with the other two subtypes, predicting its high risk and
intrinsic radioresistance, respectively. The Cl3 subtype showed an “intermediate” behavior, with all
three analyses (OS, 172-gene signature score, and RSI).
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The clinical relevance of our classification was additionally investigated and associated with
the outcome in an external validation dataset. For our analysis, we retrieved the RNA-sequencing
(RNA-seq) data of Ando et al. [23], which included 47 HPV-positive oropharyngeal squamous cell
carcinomas. With this external validation, we confirmed that the three-subtype stratification provides
useful prognostic information. As a matter of fact, better outcomes were associated with patients
belonging to Cl1/Cl3 subtypes, and worse outcomes were associated with patients belonging to Cl2
subtype (Figure 7c) (log-rank p-value = 0.0152). Finally, we investigated the association between
clinal features and our molecular stratification. Table S3 (Supplementary Materials) reports the data
related to gender, age, smoking habit, site, and TNM v7 stage. We found a significant association with
site having Cl2 a higher percentage of cases other than oropharynx. In addition, due to its potential
prognostic role, smoking habit was associated with the three subtypes. There was a trend in the different
distribution of the smoking habit with higher percentage of smokers in Cl2. Table S4 (Supplementary
Materials) reports the association for Ando’s dataset including gender, age, smoking, Ang et al. (2010)
classification system, smoked packs per year, alcohol use, t-stage, and n-stage. We found a significant
association with t-stage, having Cl2 cases a higher percentage of T3–4.
3. Discussion
Among HNSCCs, the HPV-positive tumors are an independent entity with specific clinical and
molecular characteristics. Moreover, inside the HPV-positive subgroup, it is additionally possible
to observe an intrinsic heterogeneity, in terms of patients’ outcomes. This assumption questions
whether treatment de-intensification could be applied to all HPV-positive HNSCCs. Clinical factors,
such as large tumor burden and smoking history, correlate with a worse prognosis, but the biological
mechanisms elucidating the complexity of the HPV-positive subgroup are still not fully understood.
In the present meta-analysis of transcriptomic data, we applied a rigorous and up-to-date bioinformatics
analysis to 346 HPV-positive HNSCCs with published sample data. To the best of our knowledge,
this is the largest cohort of HPV-positive HNSCCs analyzed up until now. Specifically, our study
identified three tumor subtypes, and it further dissected a population, which was previously divided
into only two subgroups by published studies [12,13,24]. In agreement with these findings, we clearly
identified an immune-associated cluster (named Cl1 in our analysis). In addition, we stratified the
remaining patients (previously described as one “keratinocyte subtype” cluster [13,24]) into two well
distinct subtypes with clearly defined biological and prognostic characteristics. The stratification
refinement could be attributed not only to the dimension of the analyzed cohort (from two to three
times larger than in previous studies), but also to the application of the NJ analysis, which revealed a
degree of heterogeneity moving from Cl2 to Cl3 samples with disjointed branches.
In general, HPV-related HNSCCs are known to have better outcomes when compared with
HPV-negative HNSCCs [25]. The observed overall survival of our cohort of patients is aligned with
the reported prognostic data. However, our analysis displayed a specific prognosis for each cluster,
identifying those HPV-positive cases with the best, intermediate, and poorest prognoses. Interestingly,
the subtype stratification did not provide evidence of a significant association with smoking habit,
but highlighted some specific biological traits for each cluster that could help in interpreting their
different outcomes.
Cluster 1 patients exhibited the best outcome at five years and it showed similar behavior to those
patients identified as having low-risk HPV-related HNSCC [25]. Additionally, Cl1 was clearly separated
from the other two clusters by its high immune score in the xCell analysis, and by upregulation of
the hallmarks “IFN, interferon gamma signaling” and “IL6 JAK STAT3 signaling”. The high immune
score, associated with a good outcome, could be in agreement with the hypothesis that, in these
patients, the immune system plays an important role in the clearance of viral proteins expressed
in HPV-positive cancers [26]. Indeed, tumors enriched by the IFN-gamma signature may benefit
from immunotherapy [27]. On the contrary, the IL6/JAK/STAT3 pathway hyper-activation is more
difficult to interpret in the context of a better prognosis. In fact, IL6/JAK/STAT3 signaling is expected
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to drive proliferation, survival, and invasiveness of tumor cells, and to suppress the anti-tumor
immune response. Overall, we could assume that, in Cl1, the immune infiltrate, as determined by the
ImmuneScore, and the high “IFN, interferon gamma signaling” could counterbalance the pro-tumoral
action of IL6 JAK STAT3 signaling; however, specific functional assays are necessary to confirm
this assumption. Considering the better prognosis and the biological profile, we could hypothesize
that Cl1 patients would be the best candidate for de-escalating treatment strategies, even including
checkpoint inhibitors.
Cluster 2 exhibited the worst outcomes, and it strongly differed from the other two subtypes by
its high stromal score. Essentially, this score reflects fibroblast infiltration, and it frequently leads to
deregulation of EMT-inducing factors, EMT upregulation, and hallmark “hypoxia” overexpression.
The EMT changes in tumor cells were reported to be linked to the acquisition of aggressive behaviors
including (i) increased invasive properties, (ii) resistance to DNA damage, (iii) chemotherapy-induced
apoptosis, (iv) immunosuppression, and (v) acquisition of stem-like features [28]. In addition,
the increase in the hallmark “hypoxia” is in agreement with the radioresistance detected by
RSI [29]. We hypothesize that treatment intensification could be beneficial for these patients. As an
example, an accelerated fractionation schedule of radiotherapy should be considered as a strategy to
overcome radioresistance.
Cluster 3, characterized by an intermediate outcome compared with the other two clusters, was
clearly defined by upregulation of the hallmarks “E2F targets” and “G2M checkpoint”, both associated
with increased proliferation. A possible explanation for these data may be the interpretation of boosted
proliferation as a result of the integration of the viral genome in the host cell. Moreover, upregulation
of the hallmarks “E2F targets” and “G2M checkpoints” is in agreement with the observation that the
HPV genome does not encode enzymes necessary for viral replication [26]. Instead, the virus utilizes
host cell proteins to replicate its DNA. Therefore, basal cells containing HPV genomes remain active in
the pathway related to the cell cycle, also due to Rb degradation. The E2F transcription factor, without
Rb function, is free to drive the expression of S-phase genes [26,30]. A first explorative investigation,
between the viral integration and our three clusters using data provided by Koneva et al. [20], revealed
a significant association between the integration of HPV in the host genome and each of our subtypes
in the following order: Cl1 < Cl3 < Cl2 (Figure S2, Supplementary Materials). Despite the analysis
being performed on a limited number of samples, Cl2 seemed to be in accordance with cases already
described in literature, in which HPV was integrated and viral integration was associated with a poor
prognosis [31]. Nevertheless, in this regard, Cl3 shows an intermediate behavior, which may possibly
be explained through Nulton discovery [32]. Indeed, HPV infection is described not only as its usual
integrated and episomal state but, additionally, as a third state where the viral genome exists as both
episomal and integrated states. Anyway, the proposed associations require further evaluation, for not
only exploring the HPV state, in terms of integration, episomal, and intermediate states, but also to
examine possible target amplification.
Some limitations of this study and some differences with more recent data should be mentioned.
Based on the clinical characteristics of the analyzed patients, we observed a relatively high number of
missing clinical data (near to 30% in age and stage). The possible explanation for the unavailability
of these data could reside in the nature of the studies included in our meta-analysis, which had the
biological description of the HPV tumors as a primary endpoint and, accordingly, an inconsistent
collection of clinical data was performed.
It is noteworthy that HPV-related tumors in subsites, other than the oropharynx, reached a
higher percentage than expected (10%). We hypothesize that this difference could be attributed to the
sample collection in the years before the clear prognostic role of HPV infection in oropharynx cancers.
In fact, the new TNM staging system (American Joint Committee on Cancer, 8th edition) distinguishes,
for the first time, HPV-related from HPV-unrelated oropharynx cancers by stratifying according to p16
expression. The prognostic value for other subsites (i.e., oral cavity, hypopharynx, larynx) other than
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the oropharynx is still debatable, although a recent review demonstrated a prognostic role for HPV
infection in all HNSCC subsites [33].
Considering the prognostic role of our stratification, three subtypes, with different outcomes,
were described for the first time. An identified limitation could be the fact that treatment was not
systematically recorded, and the overall survival of our case series was poorer than the expected
outcome [25]. Moreover, another limitation was identified: the association of subtypes and prognoses
should be underscored, although we should highlight that the follow-up was only available for 197
out of 346 (57%) cases. A further bias is related to the differences in treatment techniques used in the
last 15 years (e.g., three-dimensional (3D) vs. intensity-modulated radiotherapy; trans-oral robotic
surgery, TORS, robotics vs. traditional open surgery).
In conclusion, ongoing trials on de-escalation treatment approaches in HPV-positive HNSCC
are based only on HPV status and do not take the contributions of genomics and molecular profiles
into consideration [34]. It is conceivable that, upon rigorous validation, our stratification could help
develop a “precision treatment approach” based on the genomic profile of HPV-related HNSCC to
select patients.
4. Materials and Methods
4.1. Case Material: Gene Expression and Clinical Data
A survey of gene-expression data on HNSCC (available at 31 August 2018) was accomplished.
The cases entered into our study were selected based on the following eligibility criteria: (i) primary
lesions of squamous cell carcinoma; (ii) reported HPV status, according to the clinical practice
in the reference center; (iii) MIAME (Minimum Information about a Microarray Experiment) [35]
complaint data with the availability of raw data deposited on publicly accessible repositories and
full gene annotation (Gene Bank accession or EntrezID). After literature revision, there were 11
datasets [12,36–45]. See Table S1 (Supplementary Materials) for details regarding the datasets including
the accession numbers and methods of HPV detection. Raw microarray data were retrieved from the
NCBI (National Center for Biotechnology Information) Gene Expression Omnibus (GEO) database [46],
ArrayExpress (the EMBL European Bioinformatics Institute, UK) [47], MIAME-Vice [48], and TCGA
repositories [49] and were integrated into a unique dataset through a meta-analysis approach, as
previously described [50].
In addition, we collected available clinical data related to this case material, comprising age at
diagnosis, gender, smoking habits, tumor subsite, stage, and overall survival.
For validation purposes, we retrieved the data from Ando et al. [23], which are publicly available on
the GEO repository (identifier (ID): GSE112026). A cohort of 47 primary tumor tissues with HPV-related
oropharyngeal squamous cell carcinoma was collected for RNA-seq analysis and microdissected to
yield at least 80% tumor purity. HPV tumor status was confirmed by in situ hybridization for
high-risk HPV subtypes or p16 immunohistochemistry. According to the TCGA RSEM (RNA-Seq
by Expectation Maximization) pipeline, RNA-seq data were processed using RSEM version 1.2.9
and upper quartile normalization. For class prediction purposes, analyses were performed through
R-based BRB-ArrayTools software (version 3.5.0) developed by Richard Simon and the BRB-ArrayTools
development team [51]. A class prediction method based on a supervised learning method was applied
for classifying GSE112026 cases. Prediction was based on the support vector machine (SVM) method
by incorporating genes at the univariate significance level (α = 0.001) in a binary tree classification
framework, which was chosen due to its ability to classify more than two classes. SVM is specifically
designed to address binary classification; however, it can be adapted to handle multi-class classification
by building a sequence of binary classifiers. The prediction error of the binary tree classifier was
estimated by the leave-one-out cross-validation method.
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4.2. Data Preprocessing for Meta-Analysis Dataset Generation
The selected studies were analyzed with four platforms, including three microarray platforms
(Affymetrix, Agilent, and Nimblegene) and one RNA-seq (Illumina). For Affymetrix data, signal
intensities were normalized within each individual dataset using a robust multi-array average (RMA)
tool. For Agilent data, the normexp background correction and loess normalization were used for
two-channel arrays, while quantile normalization procedures were applied to the probe-level data.
For Illumina microarray data, quantile normalization was applied. For RNA-seq data, TCGA level 3
files were downloaded along with the clinical annotations and used for the analysis. The redundancy
of probes mapping the same EntrezID was removed by selecting the probe with the highest variance
among multiple probe-sets by identifying the same gene; collapse was performed using WGCNA
package 1.63 (function: collapseRows) and the “maxRowVariance” method [52]. To reduce the likelihood
of systemic non-biological technical experimental biases among data from different platforms, after
log2 transformation, the ComBat algorithm was applied [53]. Then, the expression value of each gene
was averaged over all samples of our data matrix, converting the expression data into the change
in log-expression (∆ei,m) of gene i in sample m; ∆ei,m = 0 implies an expression level according to its
mean value, while a relative positive or negative value refers to over- or under-expression, respectively,
according to the mean gene expression.
4.3. Tumor Clusters: First-Level SOM
The ∆ei,m data matrix was used to train a SOM, an unsupervised machine learning method based
on the artificial neural network, enabling the dimensionality reduction of complex data structures of
size N ×M (N: number of genes; M: number of samples) to K ×M (K: number of meta-genes), where
K << N, promoting the discovery of qualitative relationships among samples [54]. Each meta-gene
represents a cluster of genes sharing similar expression profiles and was selected by an interactive
machine learning process by SOM; the process was trained until the meta-genes captured the entire
range of expression patterns present in the data matrix. SOM algorithm data analysis and landscape
visualization were performed using the “oposSOM” R package (version 1.18.0) [55], which uses the
“som” R package [56]. A statistical significance criterion based on expression variance was applied
to discard the non-informative features in our data matrix through the BRB-ArrayTools developed
by Dr. Richard Simon and the BRB-ArrayTools Development Team [57]. The procedure assigns each
input gene measured in M samples into a meta-gene of the same length, and each gene is included in a
meta-gene, ∆ei,mmeta, of closest similarity established by the Euclidian distance. The meta-genes are
organized in a two-dimensional grid of K = x × y tiles with the most similar expression profiles of
meta-genes adjacent each to another, while the dissimilar ones are more distant. In the present study, we
adopted a tile size with an average of nk ≈ 10 genes per meta-gene, corresponding to a two-dimensional
grid of size K = 18 × 18 meta-genes with square topology and the Gaussian neighborhood function [14].
The meta-genes were normalized to fit into the range −1 ≤ ei,mmeta ≤ 1 and coded by a color scale from
blue (low expression) to red (high expression).
4.4. Tumor Clusters: Unsupervised Clustering Analysis
The R-package “ConsensusClusterPlus” [58] was applied to portion the samples into molecular
coherent subtypes. The meta-data ∆ei,mmeta were used as input for unsupervised class identification
using partition around medoids (PAM) clustering with 1-Pearson correlation as the distance matrix.
The PAM algorithm [59] is similar to the K-means algorithm, with both being partitional algorithms
that split the dataset into clusters and try to minimize the error. However, while K-means works
with centroids, which are artificially created entities that are representative of each cluster, PAM
chooses real data-points as cluster centers. An unsupervised clustering procedure was applied to the
data through 1000 re-sampling interactions by randomly selecting a fraction of the samples. Cluster
numbers ranging from 2 to 10 were tested, and the empirical cumulative distribution function (CDF)
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and delta area plots displaying consensus distributions were assessed to identify the number of clusters
giving maximum stability with a negligible increase in the CDF area [60]. To estimate the accuracy of
the classification, the silhouette correlation width values were calculated for all samples (R-package:
“oposSOM”), providing a graphical representation of how well the samples lay within their assigned
cluster. The silhouette values ranged from +1 to −1, indicating the degree of similarity of a sample to
the assigned cluster (cohesion) or to other clusters (separation). The evaluation of sample size adequacy
of the identified clusters was assessed according to Warnes and Liu (R-package: “ssize”) [61] and
computed by imposing the type I error rate (false discovery rate, FDR), α = 0.05, and a minimum effect
size (log fold-change) of ∆ = 1. Cluster-specific portraits represent the mean value of each meta-gene
of the samples belonging to the cluster in detail. The portraits are depicted in a log (fold-change)
scale where the fold-change is the expression difference compared with the mean expression in all
samples. To ascertain to what degree technical variability (i.e., study of origin and platform) affects
our subtype clustering analysis, we used the “alluvial diagram”, a variant of the parallel coordinates
plot that is helpful for exploring categorical data by grouping them into flows that can easily be
traced in the diagram [62]. The plots were generated using the R-package “alluvial”. In addition,
we used a linear mixed model to quantify the extent of technical variability in each sample through
the “variancePartition” R package [63]. To visualize the contribution of each variable, violin plots were
depicted to show the trend and rank the distribution of variance explained by each variable across all
genes. The plots summarize the results in terms of the percentage of variance explained.
4.5. Cluster Similarity Relationships: Second-Level SOM Cartography
Second-level SOM analysis aims to address the issue of similarity relationships among groups of
samples. It estimates the hierarchy of similarities and mutual distances based on the expression of
meta-genes, and it provides improved visualization and representativeness of the results. To infer the
main structures present in our data, we applied three approaches for computing the distance metrics.
Independent component analysis (ICA) [64] was applied to the SOM meta-genes using the
“fastICA” R package [65], a method based on the covariance matrix assessed by Pearson’s correlation to
decompose the input meta-genes into independent and non-Gaussian components in order to ensure
that each one is statistically as independent from the others as possible.
The correlation backbone through a two-nearest-neighbor graph is a correlation network approach
where Pearson correlations are computed between all pairwise combinations of samples, and their
structures are visualized in a graph.
The NJ algorithm (“ape” R package [66]) is a distance-based method offering phylogenetic tree
reconstruction where similarity trees are defined between samples into an Euclidian space, allowing
“bush-like clusters” displaying mutual dissimilarity to be revealed [67].
To visualize the main meta-genes related to subtype stratification, we assessed the group
over-expression spots. We exploited SOM portraits by detection of the coherent expression of
meta-genes. Using group overexpression maps, we linked selected meta-genes (correlation with r >
0.5) in different regions of the SOM with groups of samples. The group overexpression portrait was
calculated as the mean map profile by averaging the meta-gene expression over the three subtypes.
To identify the over-expression tiles, a 98th percentile criterion was applied to the meta-gene expression
SOM training aggregate meta-genes with similar profiles in the adjacent neighbored tiles of the map.
These tiles’ profiles grouped over-expressed (or under-expressed) samples that differed from the
others. The samples belonging to each subtype were summarized in an average representative portrait.
The mining of biological functions from SOM portraits was performed using “oposSOM” R package
(version 1.18.0).
4.6. Tumor Microenvironment Landscape
To evaluate the heterogeneity in the tumor microenvironment, the immune, stromal, and other cell
components were inferred by an in silico approach using the xCell tool [68,69]. This approach enables
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the assessment of 64 cell types using the bulk gene expression profiles of the tumors as input and
comparing them across samples, as described by the authors of Reference [69]. The tool outputs include
the transformed xCell scores for the immune, stromal, and other cell types. The adjusted ImmuneScore
included 10 populations (B-cells, CD4+ T-cells, CD8+ T-cells, DC, eosinophils, macrophages, monocytes,
mast cells, neutrophils, and NK cells) and StromaScore 3 populations (adipocytes, endothelial
cells, fibroblasts). In addition, to identify potential keratinocyte differentiation, the xCell score for
keratynocytes was computed. To visualize the cellular heterogeneity of the clusters, we applied
a dimension reduction method by t-distributed stochastic neighbor embedding (t-SNE) using the
“Rtsne” package [70], which projected the cell type enrichment scores onto two-dimensional axes [71].
We presented the scores of each subtype in notched boxplots using the “ggplot2” R package. Notch
boxplots display a confidence interval around the median based on the median±1.58× IQR (interquartile
range) /sqrt(n). They are useful graphs for comparing groups of samples, because an absence in notch
overlapping provides strong visual evidence that the medians differ. The p-values were calculated by
the Kruskal–Wallis test, a nonparametric test that compares the means among three or more groups, as
in our subtype classification.
4.7. Functional Analyses
To disclose the biological functional properties associated with the proposed molecular subtypes,
gene set analysis was applied. This approach estimates gene set over-representation (probability
of finding genes in a list compared to their random appearance) and over-expression (difference in
expression compared to the mean expression over the samples). The gene sets were defined from a
priori knowledge from independent studies and they were summarized in a list of genes specifically
related to molecular pattern/biological function. A large collection of gene sets was retrieved from
the Gene Set Enrichment Analysis (GSEA Broad Institute; software.broadinstitute.org/gsea/) and the
Molecular Signatures Database (MSigDB) repository, including 50 hallmark gene sets. We used the
gene set Z-score (GSZ) to summarize the profile of a gene set across all samples [72]. GSZ is a Z-score
function that merges both over-representation and over-expression features from a gene set to give a
defined gene set and provides a representative score of the gene set for each sample. Boxplots were
generated using the “ggplot2” R package with the notched boxplot function (see Section 4.6).
4.8. Analysis of Viral Presence/Integration and Its Association with Clusters
The association between viral integration and our subtype stratification was investigated using
the results provided by Koneva et al. [20]. Based on TCGA RNA-seq data and exploiting VirusSeq
software [73], they detected known virus strains and identified the integration sites. Thus, the authors
disclosed the HPV integration status of 65 TCGA cases present in our meta-analysis and assessed
viral gene expression (E2, E4, and E5). We investigated the relative presence of integrated HPV cases
defined as integrated cases/(integrated + non-integrated cases) in each subtype, and significance was
calculated by the χ2 test. Counts per million (CPM) were retrieved from Koneva et al. and transformed
into the log scale by log2(CPM + 1) [74]. Associations with viral gene expression were visualized by a
heatmap. The samples were ranked by the Gene Set Variation Analysis (GSVA [75]) based on the three
viral genes. GSVA was used to estimate the variation of a gene set over the samples in an unsupervised
manner. The p-values were calculated by the Kruskal–Wallis test.
4.9. Evaluation of Prognostic Signatures
Statistical analysis was performed using R (version 3.5.1) [76] and Bioconductor (release 3.7) [77].
Survival curves were assessed according to the Kaplan–Meier method, and overall survival was
used as the endpoint. Differences between the subtypes were assessed using the log-rank test and R
package “survival”. Two signatures were evaluated: (i) the 172-gene prognostic model [21]; (ii) the
radiosensitivity index (RSI) [22]. The list of genes and the algorithm used for model assessment were
retrieved from the original papers.
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s1: Figure S1: Estimation of sample size adequacy. The relationship between the genes in our data matrix and
power to detect a sample size defined by our three-subtype stratification (Cl1 = 134; Cl2 = 104; Cl3 = 108) is shown
in the plots. The percentage of genes achieving a power level of at least 0.9 is displayed by the red bars and was
calculated by performing a pairwise comparison between subtypes; Figure S2: Violin and boxplot of the percent
variation in gene expression explained by the study of origin, platform, and our three-cluster stratification. Median
percentage variation explained: cluster = 50.4%; study <1%; platform <1%; Figure S3: Expression heatmap of
viral genes. The expression values for HPV E2, E4, and E5 in the TCGA cases were retrieved from Koneva et al.
For visualization purposes, samples were ranked based on Gene Set Variation Analysis (GSVA) from low to high
viral gene enrichment. The membership of each TCGA sample is depicted in the bar below the heatmap. Low E2,
E4, and E5 expression was found in Cl2 cases compared with Cl1 and Cl3 (p-value = 0.00156, p-value = 0.00204,
and p-value = 0.00147 determined by Kruskal–Wallis Tests, respectively); Table S1: List of used datasets. Dataset
name, platform used, provider, technology, repository (included websource), number of samples, assignment
to the three clusters, and methods of HPV detection are detailed in the table for each of the 11 sources utilized;
Table S2: Contingency table for TCGA HPV cases annotated for HPV integration status by Koneva et al; Table
S3: Association to clinical parameters in the meta-analysis dataset. The table includes the evaluation of the
following clinical parameters: (i) gender; (ii) age; (iii) smoking habit (current or former smokers vs. never smoke);
(iv) site (oropharynx vs. other sites); (v) stage. p-values by χ2 test, with the exception for age determined by
Kruskal–Wallis Tests; Table S4: Association to clinical parameters in the validation dataset (GSE112026). The table
includes the evaluation of the following clinical parameters: (i) gender; (ii) age; (iii) smoking, (iv) Ang et al. (2010)
classification system; (v) smoked packs per year; (vi) alcohol use; (vii) t-stage; (viii) n-stage. p-values by χ2 test,
with the exception for age determined by Kruskal–Wallis Tests.
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